Related Experiment Video

Updated: Apr 9, 2026

Author Spotlight: Effect of Left Atrial Ligation on Avian Embryonic Hearts and HLHS Implications
04:37

Author Spotlight: Effect of Left Atrial Ligation on Avian Embryonic Hearts and HLHS Implications

Published on: June 16, 2023

1.9K

Hypoplastic left heart in the 6500-year-old Detmold Child

Nikolaus A Haas1, Michael Zelle2, Wilfried Rosendahl3

  • 1Department for Congenital Heart Defects, Heart and Diabetes Centre North Rhine Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.

Lancet (London, England)
|June 20, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse
08:19

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse

Published on: December 16, 2022

2.6K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.7K

Related Experiment Videos

Last Updated: Apr 9, 2026

Author Spotlight: Effect of Left Atrial Ligation on Avian Embryonic Hearts and HLHS Implications
04:37

Author Spotlight: Effect of Left Atrial Ligation on Avian Embryonic Hearts and HLHS Implications

Published on: June 16, 2023

1.9K
A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse
08:19

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse

Published on: December 16, 2022

2.6K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.7K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

749
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
749
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

786
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786

Articles linked to this work by shared authors, journal, and citation graph.

Pediatric extracorporeal membrane oxygenation support at a single center: Outcomes by indication, prognostic factors, and duration.

Annals of pediatric cardiology·2026

Microcirculatory effects of heparin: Evidence for endothelial glycocalyx degradation in children and young adults.

Microvascular research·2026

An unusual case of persistent very low-voltage electrocardiography.

Cardiology in the young·2026

Before "Back to Sleep": Deformational plagiocephaly and pediatric insights from Iron Age Italy.

International journal of paleopathology·2026

The Winthir Collection: An Identified Historical Skeletal Series From Munich, Germany.

American journal of biological anthropology·2026

Characterization of complex New Kingdom funerary resinous mixtures uncovers liquorice-derived substances and pine nut oil.

Scientific reports·2026

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us